Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2024.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world’s largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that it has completed the repurchase of $1 billion (1.9 million shares) of its common stock. As of December 3, 2024, $3 billion remained available under the company’s share repurchase authorization.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company’s existing repurchase authorization, of which $1 billion was remaining.

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQMYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. NYSE: TMONYSETMO)

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Wolfe Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. (EDT).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on January 15, 2025, to shareholders of record as of December 13, 2024.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2024.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2024 before the market opens on Wednesday, October 23, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.

Here are brief overviews of five Nasdaq stocks, tailored to highlight their strengths and receive public attention:

Pre-market trading is heating up as Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) surges on positive Phase 2 data for its cancer treatment BDTX-1535. Peraso Inc. (NASDAQPRSO) continues its expansion into the Asian markets and a major military contract. Kaival Brands NASDAQ: KAVLNASDAQKAVL)(NASDAQ: BNZINASDAQBNZI, which saw a 97.51% rally after announcing a favorable share structure, Battalion Oil Corp (NASDAQ: BATLNASDAQ) on merger news, and Treasure Global Inc. (NASDAQ: TGLTGL) , experiencing unusual high volume on its innovative ZCITY Super App. Keep these stocks on your radar for potential moves. See more in-depth information below.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, hosted its 2024 Investor Day today and provided an in-depth review of the company’s proven growth strategy and its industry-leading businesses, which consistently deliver best-in-class products and services that are essential to the work performed by its customers around the world.

Agilent Technologies Inc. (NYSEA) is a diversified global leader in the life sciences, diagnostics and applied chemical markets.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 8:30 a.m. (EDT).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on October 15, 2024, to shareholders of record as of September 13, 2024.

To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, is partnering with the National Cancer Institute (NCI) – part of the National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. By testing patients’ bone marrow and blood for certain genetic biomarkers using Thermo Fisher’s next-generation sequencing (NGS) technology, clinical sites can more quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment.

UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the UK Competition and Markets Authority (the “CMA”) has unconditionally approved the previously announced tender offer (the “Offer”) by Orion Acquisition AB (the “Buyer”), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher” or “Parent”), for all outstanding Common Shares and American Depositary Shares (together, the “Shares”) of Olink for $26.00 per Share.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2024 before the market opens on Wednesday, July 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously announced tender offer (the “Offer”) to acquire all of the outstanding common shares (“Shares”) and all of the outstanding American Depositary Shares, each representing one Share (“ADSs”), of Olink Holding AB (publ) (“Olink”) for $26.00 per Share and per ADS, in cash.

The fastest-growing dividends in the S&P 500 are good buys, but that doesn't mean it's time to buy them now; only one is accelerating distribution growth.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast throughput, high sensitivity, and ease of use to allow researchers to advance their translational omics research and make breakthrough discoveries more efficiently.